Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.50 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18020598 | 0.88 | KMT2A (0.57) | NPC1KMT2APOLBGAAKDM4E | |
| SCHEMBL15580586 | 0.84 | KMT2A (0.54) | NPC1KMT2APOLBGAAKDM4E | |
| SCHEMBL2462911 | 0.84 | KDM4E (0.71) | NPC1KMT2APOLBGAAKDM4E | |
| SCHEMBL29290132 | 0.81 | KMT2A (0.60) | NPC1KMT2APOLBGAAKDM4E | |
| SCHEMBL28813458 | 0.81 | CACNA1B (0.59) | NPC1KMT2APOLBGAAKDM4E | |
| SCHEMBL17986146 | 0.80 | KMT2A (0.52) | NPC1KMT2APOLBGAAKDM4E | |
| SCHEMBL17424467 | 0.78 | HPGD (0.63) | NPC1KMT2APOLBGAAKDM4E | |
| SCHEMBL8367791 | 0.77 | KMT2A (0.78) | KMT2APOLBGAAKDM4EMAPT | |
| SCHEMBL16610051 | 0.77 | KMT2A (0.46) | NPC1KMT2APOLBGAAKDM4E | |
| SCHEMBL16171213 | 0.76 | NPC1 (0.63) | NPC1KMT2APOLBGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3049386-B9 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIV KOELN (DE) | 2020-11-18 | — | — | EP | disclosed |
| EP-3049386-B9 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIV KOELN (DE) | 2020-11-18 | — | — | EP | disclosed |
| US-10793509-B2 | Compounds useful in the treatment of neoplastic diseases | UNIVERSITÄT ZU KOLN (DE) | 2020-10-06 | — | — | US | disclosed |
| US-10793509-B2 | Compounds useful in the treatment of neoplastic diseases | UNIVERSITÄT ZU KOLN (DE) | 2020-10-06 | — | — | US | disclosed |
| EP-3049386-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIV KOELN (DE) | 2020-07-22 | — | — | EP | disclosed |
| EP-3049386-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIV KOELN (DE) | 2020-07-22 | — | — | EP | disclosed |
| US-20160237023-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2016-08-18 | — | — | US | disclosed |
| US-20160237023-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2016-08-18 | — | — | US | disclosed |
| US-20160237023-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2016-08-18 | — | — | US | disclosed |
| WO-2015044177-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237023-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | APC, BRCA1, VHL | NPC1 794/4885KMT2A 3041/4885POLB 185/4885 |
| US-10793509-B2 | Compounds useful in the treatment of neoplastic diseases | APC, BRCA1, VHL | NPC1 794/4885KMT2A 3041/4885POLB 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.